Effect of dopamine uptake inhibition on brain catecholamine levels and locomotion in catechol-O-methyltransferase-disrupted mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 303, Issue 3, 2002, Pages 1309-1316

  Huotari, Marko ^a   Santha, Miklos ^b   Lucas, Louis R ^b   Karayiorgou, Maria ^b   Gogos, Joseph A ^c   Männistö, Pekka T ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b ROCKEFELLER UNIVERSITY   (United States)

^c Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; COCAINE; VANOXERINE;

ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BIOACCUMULATION; BRAIN CORTEX; BRAIN TISSUE; CATECHOLAMINE BRAIN LEVEL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BLOOD LEVEL; DOPAMINE UPTAKE; DRUG EFFECT; DRUG INHIBITION; EXTRACELLULAR FLUID; HYPERACTIVITY; HYPOTHALAMUS; LOCOMOTION; MALE; MOUSE; NERVE ENDING; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; BRAIN; CATECHOL O-METHYLTRANSFERASE; CATECHOLAMINES; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; FEMALE; LOCOMOTION; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT MODULATORS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NERVE TISSUE PROTEINS;

EID: 0036896470     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.043042     Document Type: Article

References (40)

1. Andersen PH (1989) The dopamine inhibitor GBR 12909: Selectivity and molecular mechanism of action. Eur J Pharmacol 166:493-504.
2. Borgulya J, Bruderer H, Bernauer K, Zürcher G, and Da Prada M (1989) Catechol-O-methyltransferase-inhibiting pyrocatechol derivatives: Synthesis and structure-activity studies. Helv Chim Acta 72:952-968.
3. Borowsky B, Adham N, Jones KA, Raddatz R, Artymyshyn R, Ogozalek KL, Durkin MM, Lakhlani PP, Bonini JA, Pathirana S, et al. (2001) Trace amines: Identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci USA 98:8966-8971.
4. Budygin EA, Gainetdinov RR, Kilpatrick MR, Rayevsky KS, Männistö PT, and Wightman RM (1999) Effect of tolcapone, a catechol-O-methyltransferase inhibitor, on striatal dopaminergic transmission during blockade of dopamine uptake. Eur J Pharmacol 370:125-131.
5. Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI, Darland T, Suchland KL, Pasumamula S, Kennedy JL, et al. (2001) Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol 60:1181-1188.
6. Butcher SP, Fairbrother IS, Kelly JS, and Arbuthnott GW (1990) Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum. J Neurochem 55:981-988.
7. Cases O, Seif I, Grimsby J, Gaspar P, Chen K, Pournin S, Muller U, Aguet M, Babinet C, Shih JC, et al. (1995) Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA. Science (Wash DC) 268:1763-1766.
8. Chen L, He M, Sibille E, Thompson A, Sarnyai Z, Baker H, Shippenberg T, and Toth M (1999) Adaptive changes in postsynaptic dopamine receptors despite unaltered dopamine dynamics in mice lacking monoamine oxidase B. J Neurochem 73:647-655.
9. Fauchey V, Jaber M, Caron MG, Bloch B, and Le MC (2000) Differential regulation of the dopamine D1, D2 and D3 receptor gene expression and changes in the phenotype of the striatal neurons in mice lacking the dopamine transporter. Eur J Neurosci 12:19-26.
10. Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, and Caron MG (1999) Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science (Wash DC) 283:397-401.
11. Giros B, Jaber M, Jones SR, Wightman RM, and Caron MG (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature (Lond) 379:606-612.
12. Gogos JA, Morgan M, Luine V, Santha M, Ogawa S, Pfaff D, and Karayiorgou M (1998) Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci USA 95:9991-9996.
13. Heikkila RE and Manzino L (1984) Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: Specific inhibitors of dopamine uptake. Eur J Pharmacol 103:241-248.
14. Huotari M, Gainetdinov R, and Männistö PT (1999) Microdialysis studies on the action of tolcapone on pharmacologically-elevated extracellular dopamine levels in conscious rats. Pharmacol Toxicol 85:233-238.
15. Huotari M, Gogos JA, Karayiorgou M, Koponen O, Forsberg M, Raasmaja A, Hyttinen J, and Männistö PT (2002) Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice. Eur J Neurosci 15:246-256.
16. Irifune M, Nomoto M, and Fukuda T (1995) Effects of GBR 12909 on locomotor activity and dopamine turnover in mice: Comparison with apomorphine. Eur J Pharmacol 272:79-85.
17. Jones SR, Gainetdinov RR, Hu XT, Cooper DC, Wightman RM, White FJ, and Caron MG (1999) Loss of autoreceptor functions in mice lacking the dopamine transporter. Nat Neurosci 2:649-655.
18. Jones SR, Gainetdinov RR, Jaber M, Giros B, Wightman MR, and Caron MG (1998) Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci USA 95:4029-4034.
19. Jori A, Colturani F, Dolfini E, and Rutczynski M (1976) Modifications of the striatal dopamine metabolism during the estrus cycle in mice. Neuroendocrinology 21:262-266.
20. Kaakkola S and Wurtman RJ (1992) Effects of COMT inhibitors on striatal dopamine metabolism: A microdialysis study. Brain Res 587:241-249.
21. Karhunen T, Tilgmann C, Ulmanen I, and Panula P (1995) Catechol-O-methyltransferase (COMT) in rat brain: Immunoelectron microscopic study with an antiserum against rat recombinant COMT protein. Neurosci Lett 187:57-60.
22. Koob GF (1992) Drugs of abuse: Anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 13:177-184.
23. Kuhar MJ, Ritz MC, and Boja JW (1991) The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 14:299-302.
24. Li YH, Wirth T, Huotari M, Laitinen K, MacDonald E, and Männistö PT (1998) No change of brain extracellular catecholamine levels after acute catechol-O-methyltransferase inhibition: A microdialysis study in anaesthetized rats. Eur J Pharmacol 356:127-137.
25. Lucas LR, Pompei P, and McEwen BS (2000) Salt appetite in salt-replete rats: Involvement of mesolimbic structures in deoxycorticosterone-induced salt craving behavior. Neuroendocrinology 71:386-395.
26. Männistö PT and Kaakkola S (1989) New selective COMT inhibitors: useful adjuncts for Parkinson's disease? Trends Pharmacol Sci 10:54-56.
27. Männistö PT and Kaakkola S (1999) Catechol-O-methyltransferase (COMT): Biochemistry, molecular biology, pharmacology and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51:593-628.
28. Moghaddam B and Bunney BS (1989) Differential effect of cocaine on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens: Comparison to amphetamine. Synapse 4:156-161.
29. Moron JA, Brockington A, Wise RA, Rocha BA, and Hope BT (2002) Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: Evidence from knock-out mouse lines. J Neurosci 22:389-395.
30. Nakachi N, Kiuchi Y, Inagaki M, Inazu M, Yamazaki Y, and Oguchi K (1995) Effects of various dopamine uptake inhibitors on striatal extracellular dopamine levels and behaviours in rats. Eur J Pharmacol 281:195-203.
31. Nakazato T and Akiyama A (2002) Behavioral activity and stereotypy in rats induced by L-DOPA metabolites: A possible role in the adverse effects of chronic L-DOPA treatment of Parkinson's disease. Brain Res 930:134-142.
32. Nestler EJ and Aghajanian GK (1997) Molecular and cellular basis of addiction. Science (Wash DC) 278:58-63.
33. Rahman S, Engleman E, Simon J, and McBride WJ (2001) Negative interaction of dopamine D2 receptor antagonists and GBR 12909 and GBR 12935 dopamine uptake inhibitors in the nucleus accumbens. Eur J Pharmacol 414:37-44.
34. Ralph RJ, Paulus MP, Fumagalli F, Caron MG, and Geyer MA (2001) Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: Differential effects of D1 and D2 receptor antagonists. J Neurosci 21:305-313.
35. Reith ME, Coffey LL, Xu C, and Chen NH (1994) GBR 12909 and 12935 block dopamine uptake into brain synaptic vesicles as well as nerve endings. Eur J Pharmacol 253:175-178.
36. Segal DS and Kuczenski R (1994) Behavioral pharmacology of amphetamine, in Amphetamine and its Analogues: Psychopharmacology, Toxicology and Abuse (Cho AK and Segal DS eds) pp 115-150, Academic Press, San Diego.
37. Self DW and Nestler EJ (1995) Molecular mechanisms of drug reinforcement and addiction. Annu Rev Neurosci 18:463-495.
38. Sesack SR, Hawrylak VA, Matus C, Guido MA, and Levey AI (1998) Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J Neurosci 18:2697-2708.
39. Westerink BH, Damsma G, De VJB, and Koning H (1987) Dopamine re-uptake inhibitors show inconsistent effects on the in vivo release of dopamine as measured by intracerebral dialysis in the rat. Eur J Pharmacol 135:123-128.
40. Zhuang X, Oosting RS, Jones SR, Gainetdinov RR, Miller GW, Caron MG, and Hen R (2001) Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc Natl Acad Sci USA 98:1982-1987.